BALTIMORE, May 17, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced positive clinical trial results on two of its advanced innovations in surgical heart valves for the treatment of people with aortic valve disease. Data from three studies—COMMENCE, TRANSFORM and FOUNDATION—were presented as part of the late-breaking sessions at the American Association for Thoracic Surgery's (AATS) 96th annual meeting.
"Edwards is proud to lead the innovation of heart valve therapies to address a broad range of patient needs around the world, and these compelling new data on more than 2,000 patients provide important clinical evidence on the benefits of new surgical treatments," said Bernard Zovighian, Edwards' corporate vice president, surgical heart valve therapy. "We are committed to expanding our surgical heart valve portfolio with meaningful innovations and by continuing to work in partnership with surgeons to meet the needs of patients who suffer from a variety of heart valve diseases."
COMMENCE Trial Data
Data from 673 patients in the COMMENCE pivotal trial demonstrated early safety and effectiveness of Edwards' surgical aortic valve featuring RESILIA tissue, a novel tissue platform. Beyond delivering strong safety results, the new valve with RESILIA tissue showed no cases of structural valve deterioration, valve thrombosis or nonstructural valve dysfunction at one year.
"The early clinical results with the new valve with RESILIA tissue in this multicenter, international FDA trial are encouraging and set a high benchmark for surgical aortic valve replacement," said John D. Puskas, M.D., chair of cardiothoracic surgery at Mount Sinai Beth Israel and director of surgical coronary revascularization at Mount Sinai Health System, New York, NY. He is the national principal investigator of the COMMENCE study. "The RESILIA tissue has the potential to create a new class of surgical tissue valves that pre-clinical studies have shown to offer key benefits, such as significantly reduced calcification and sustained hemodynamics."
TRANSFORM and FOUNDATION Trial Data
Also at AATS, the TRANSFORM pivotal trial data at one year showed that the EDWARDS INTUITY valve system, a cutting-edge rapid deployment system for surgical aortic valve replacement, is safe and effective and may reduce cross-clamp time and cardiopulmonary bypass time, compared to times recorded in the Society of Thoracic Surgeons' (STS) Adult Cardiac Database. This may provide patient benefits such as decreased mortality and morbidity, less time in an intensive care unit and reduced total hospital stay. In the study, 839 patients were treated with this device, which is built on the trusted PERIMOUNT tissue valve platform incorporating innovations from transcatheter heart valves. It evaluated both the first-generation EDWARDS INTUITY valve (n=109) and the second-generation EDWARDS INTUITY Elite valve (n=730).
In addition, the FOUNDATION registry studied the real-world experience of 493 patients who were treated with the first-generation EDWARDS INTUITY valve system in Europe, with results demonstrating excellent safety and effectiveness at one year.
"There is a clinical need for innovative surgical heart valve therapies to ensure patients receive the appropriate treatment, and the EDWARDS INTUITY Elite valve system is designed to facilitate minimally invasive surgery and streamline complex aortic valve replacements, which is a major advancement," said Walter Randolph Chitwood, Jr., MD., founder of the East Carolina Heart Institute of East Carolina University, Greenville, NC. He is a co-principal investigator of the TRANSFORM study.
Valves with the investigational RESILIA tissue are being studied as part of the COMMENCE trial, a global clinical program with three study groups: aortic, mitral and pulmonary. Data presented at AATS reported on the aortic arm of the program. The mitral study is enrolling patients, and the pulmonary study for congenital patients, including children and young adults, began enrollment in late 2015.
The second generation EDWARDS INTUITY Elite valve system was approved for commercial sale in Europe in 2014; it is not available for sale in the United States.
About Edwards Lifesciences
Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.edwards.com and follow us on Twitter at @EdwardsLifesci.
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, statements by Mr. Zovighian, Dr. Chitwood, and Dr. Puskas and expectations regarding the products' potential benefits and risks. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors, including but not limited to, unanticipated outcomes of longer term clinical experience with the products, or unanticipated manufacturing, quality or regulatory delays or issues. These and other additional factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2015. These filings, along with important safety information about our products, may be found at edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo, COMMENCE, EDWARDS INTUITY, EDWARDS INTUITY Elite, FOUNDATION, PERIMOUNT, RESILIA and TRANSFORM are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/edwards-surgical-heart-valve-innovations-demonstrate-positive-patient-benefits-300268553.html
SOURCE Edwards Lifesciences Corporation